G. Ghetti, C. Porta, and M. Povero, “Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy”, FE, vol. 26, no. 1, Mar. 2025.